Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19

BACKGROUND AND AIM: Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management of this complication. METHODS: The retrospective study included COVID-19 patients with C-reactiv...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Pulm Pharmacol Ther
Auteurs principaux: Maslennikov, Roman, Ivashkin, Vladimir, Vasilieva, Ekaterina, Chipurik, Maxim, Semikova, Polina, Semenets, Victoria, Russkova, Tatyana, Levshina, Anna, Grigoriadis, Diana, Magomedov, Shamil, Efremova, Irina, Dzhakhaya, Natiya
Format: Artigo
Langue:Inglês
Publié: Elsevier Ltd. 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8137353/
https://ncbi.nlm.nih.gov/pubmed/34023513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pupt.2021.102039
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires